Acute Repetitive Seizures - Global Market Trajectory & Analytics

Global Acute Repetitive Seizures Market to Reach $5.2 Billion by 2027

Amid the COVID-19 crisis, the global market for Acute Repetitive Seizures estimated at US$437.3 Million in the year 2020, is projected to reach a revised size of US$5.2 Billion by 2027, growing at a CAGR of 42.4% over the analysis period 2020-2027. Diastat Rectal Gel, one of the segments analyzed in the report, is projected to record a 44.5% CAGR and reach US$2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the USL-261 segment is readjusted to a revised 37.3% CAGR for the next 7-year period.

The U.S. Market is Estimated at $117.2 Million, While China is Forecast to Grow at 49.7% CAGR

The Acute Repetitive Seizures market in the U.S. is estimated at US$117.2 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2027 trailing a CAGR of 49.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 35.2% and 39.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 37.8% CAGR.

NRL-1 Segment to Record 45% CAGR

In the global NRL-1 segment, USA, Canada, Japan, China and Europe will drive the 43.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$66.5 Million in the year 2020 will reach a projected size of US$840.6 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$797 Million by the year 2027, while Latin America will expand at a 47.2% CAGR through the analysis period.

Select Competitors (Total 36 Featured):

• Alexza Pharmaceuticals
• Bausch Health
• Neurelis
• Pfizer Inc.
• Sanofi
• UCB S.A.
• Valeant Pharmaceuticals North America LLC.
• Veriton Pharma